Benznidazole in Chagas disease study: do the data justify progression to phase 3? - Authors' reply.

Simple item page
dc.contributor.authorTorrico, Faustino
dc.contributor.authorBarreira, Fabiana
dc.contributor.authorStrub-Wourgaft, Nathalie
dc.contributor.authorRibeiro, Isabella
dc.contributor.authorSosa-Estani, Sergio
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-24T15:04:01Z
dc.date.available2026-03-24T15:04:01Z
dc.date.issued2021
dc.descriptionVol. 21, No. 8, pp. 1067
dc.description.sponsorshipFundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), and Universidad Mayor de San Simón, Cochabamba, Bolivia. | Drugs for Neglected Diseases Initiative Latin America, Rio de Janeiro, Brazil. | Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
dc.identifier.doi10.1016/S1473-3099(21)00336-4
dc.identifier.issn1474-4457
dc.identifier.otherPMID:34331879
dc.identifier.urihttps://doi.org/10.1016/S1473-3099(21)00336-4
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/101003
dc.language.isoeng
dc.relation.ispartofThe Lancet. Infectious diseases
dc.sourcePubMed
dc.titleBenznidazole in Chagas disease study: do the data justify progression to phase 3? - Authors' reply.
dc.typeArtículo Científico Publicado

Files

Collections

Artículo Científico Publicado